CHMP recommends drug for relapsed/refractory cHL

Pembrolizumab (Keytruda)
Photo courtesy of Merck
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the anti-PD-1 therapy pembrolizumab (Keytruda) as a treatment for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The recommendation pertains specifically to adults with cHL who have... [Read Article]

Most blood cancer mutations due to DNA replication errors

DNA helices
Image courtesy of the
National Institute of
General Medical Sciences
A new study supports the idea that most cancer-driving mutations are a result of DNA replication errors, not heredity or lifestyle/environmental factors. For all 32 cancer types studied, researchers found that 66% of driver mutations resulted from DNA replication errors,... [Read Article]

Immunotherapy receives fast track designation

EBV-infected cell (green/red) among uninfected cells (blue)
Image courtesy of Benjamin Chaigne-Delalande
The US Food and Drug Administration (FDA) has granted fast track designation to CMD-003 (baltaleucel-T) for patients with relapsed/refractory lymphoma and post-transplant lymphoproliferative disease associated with Epstein-Barr virus (EBV). CMD-003 consists of patient-derived T cells that have been activated to kill malignant cells... [Read Article]

Styrene exposure linked to myeloid leukemia, HL

Wind turbines in Styria, Austria. Styrene is used in the manufacture of wind turbines.
A new study links styrene—a chemical used in the manufacture of plastics, rubber, and resins—to certain cancers. The research showed that, contrary to previous suggestions, employees who have worked with styrene do not have an increased incidence of esophageal, pancreatic,... [Read Article]

How EBV causes lymphoma, other cancers

EBV-infected cell (green/red)
among uninfected cells (blue)
Image courtesy of
Benjamin Chaigne-Delalande
New research published in Nature Communications appears to explain how Epstein-Barr virus (EBV) reprograms cells into cancer cells. Investigators said they discovered a mechanism by which EBV particles induce chromosomal instability without establishing a chronic infection, thereby conferring a risk... [Read Article]

Study quantifies 5-year survival rates for blood cancers

Cancer patient receiving
Photo by Rhoda Baer

A new study shows that 5-year survival rates for US patients with hematologic malignancies have increased greatly since the 1950s, but there is still room for improvement, particularly for patients with acute myeloid leukemia (AML). Researchers found the absolute difference in improvement for 5-year survival... [Read Article]